Phase 1/2a Study of ANPD001 in Parkinson Disease
NCT: NCT06344026 · ENROLLING_BY_INVITATION
Brief Summary
This clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease. All participants will have ANPD001 cells manufactured from their own previously collected cells.
Frequently Asked Questions
What is Phase 1/2a Study of ANPD001 in Parkinson Disease?
Phase 1/2a Study of ANPD001 in Parkinson Disease is a clinical trial registered under NCT06344026. Current status: ENROLLING_BY_INVITATION.
What is the status of NCT06344026?
The current status of NCT06344026 (Phase 1/2a Study of ANPD001 in Parkinson Disease) is: ENROLLING_BY_INVITATION.
When did Phase 1/2a Study of ANPD001 in Parkinson Disease start?
Phase 1/2a Study of ANPD001 in Parkinson Disease started on 2024-01-23.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.